Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies

Investigator: Pamela Munster, MD

Location(s): United States


This is a study of INCB054329 given to patients with advanced malignancies that will be conducted in three treatment groups. Each treatment group will have two parts; a dose escalation (Part 1) and an expansion (Part 2).